WAYL.CN - Wayland Group Corp.

Canadian Sec - Canadian Sec Delayed Price. Currency in CAD

Wayland Group Corp.

845 Harrington Court
Unit 3
Burlington, ON L7N 3P3
Canada
647-643-7665
http://www.waylandgroup.com

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Full Time Employees68

Key Executives

NameTitlePayExercisedYear Born
Mr. Benjamin Allan WardCEO & Director2.82MN/A1980
Mr. Scott M. LangilleChief Financial Officer303kN/A1957
Mr. Matthew McLeodPresN/AN/AN/A
Dr. James HyssenChief Operating OfficerN/AN/AN/A
Dr. Steven Prescott BennettChief Scientific OfficerN/AN/AN/A
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

Wayland Group Corp. produces and sells medical and non-medical cannabis for cannabis patients and consumers in Canada and internationally. It offers a range of CBD, balanced, and THC strains under the Kiwi, Northern Harvest, High Tide, Lost at Seed, Solara C, Rare Dankness, and Maricann names. The company was founded in 2013 and is headquartered in Burlington, Canada. Wayland Group Corp. is a subsidiary of Maricann Group Inc.

Corporate Governance

Wayland Group Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.